The facts

  1. Net sales rose 16.2% at actual exchange rates and 14.3% at constant exchange rates from the same quarter in 2025. [1]

  2. Business EPS, a non-IFRS measure, rose 22.0% at actual exchange rates and 19.6% at constant rates. IFRS EPS was €2.52; these are different earnings measures. [1]

  3. Dupixent sales reached €5.7 billion, up 34.8% at constant exchange rates. Vaccine sales were €3.2 billion, down 6.6% on that basis. [1][2]

  4. Sanofi now forecasts low-teens percentage sales growth and mid-teens business-EPS growth for 2026 at constant exchange rates. These are forecasts, not completed full-year results. [1][2]

Still unconfirmed

  • Final full-year results remain unknown. No compatible named-provider consensus comparison is established in the checked material.

Sources

References support the numbered facts above. Source checks: 30 Oct 2026, 08:54 UTC.

  1. Q3 2026 results

    Sanofi · Primary source · 30 Oct 2026

    Actual issuer release read, published at 06:30 UTC. Business/non-IFRS and IFRS measures and actual/constant-currency growth are kept separate.

  2. Sanofi Q3 earnings blow past expectations on Dupixent strength; hikes FY guidance

    Investing.com / Ambar Warrick, via Yahoo Finance · Reporting · 30 Oct 2026

    Actual07:22 UTC report read. Investing.com is separate from Sanofi; Yahoo is its host, not another reporting owner. The report's estimate has no named consensus provider, so no exact earnings beat or percentage miss is adopted.

Report a factual error